Categories

Category: THCB Spotlights

Roy Schoenberg, CEO, AmWell

AmWell is a now veteran telehealth platform. It used its IPO money to re-architect its entire platform and add companies like Conversa AI chat service and mental health service Silvercloud, as well as integrating deeply with EMRs & more. That change hit its earnings….so can they recover? Roy Schoenberg, CEO, tells you why this is good for AmWell and what happens next.-Matthew Holt

Lucienne Ide, Rimidi

Lucie Ide is a physician running Rimidi, a company helping health systems manage patients with chronic conditions. They extract data from EMRs and transfer this into workflow for care teams, predominantly at ACOs and other risk bearing organizations, but also increasingly with FFS groups using RPM to manage those patients. Their current moves are to continue to extend from their first patient group (diabetes) to all types of chronic patients. We chatted about her company, but also about the wider move (or lack of it) to better manage patients in the US system–Matthew Holt

Raj Singh, Accolade

Earlier this month I caught up with Raj Singh, the CEO of Accolade. The “navigation” company is publicly traded and now offering its own telehealth, primary care & second opinions as well as helping patients access both digital health services and brick & mortar health systems. How is Accolade dealing by both offering primary care and helping patients manage through complex care situations? And why isn’t this available to everyone, yet? Raj told me how it works and what the likely future will be, including work with health plans, and how Accolade is on a path to a $1b in revenue in 5 years.–Matthew Holt

Kota Kubo, Ubie

Kota Kubo is the CEO of Ubie, a Japan-based symptom-checking company. Ubie has raised over $75m including a $45m round in 2022. They were focusing on the Japanese market but have been available in the US since 2022, and are expanding their presence there dramatically in 2024. It’s a direct to consumer product with a business model of helping pharma companies understand their patients better–while of course not letting them have patients’ private or identifiable information. This is a little different than most symptom checkers who tend to work with providers or plans, and I met Kota in Tokyo late last year to discuss the business and get a little demo–Matthew Holt

Nicola Tessler, CEO, BeMe Health

Nikki Tessler is the CEO of BeMe Health. She is a psychologist who has built a relatively new company with a self service tool and coaching service for teens. It’s essentially trying to convert teens’ social media time to good use with support, affirmations, coaching and safety–and much more.. I interviewed Nikki and got a full demo over the holiday break. There’s a lot of information here about the teen mental health question (yes it’s bad!), about the company funding & strategy, and great understanding of the product…which is pretty unusual and growing fast!Matthew Holt

THCB Gang Special: Episode 138, Thursday 30 November 2023 with Jen Goldsack

On #THCBGang today we have a special solo episode with Olympic rower for 2 countries and Digital Medicine Society CEO Jennifer Goldsack, (@GoldsackJen) joining Matthew Holt (@boltyboy). It’s at at 1pm PST 4pm EST on Thursday November 30. Find out about what DiME is and does, and what projects it is pushing forward in the future of health tech.

You can see the video below & if you’d rather listen than watch, the audio is preserved as a weekly podcast available on our iTunes & Spotify channels.

THCB Gang Episode 137, Thursday October 26

Joining Matthew Holt (@boltyboy) on #THCBGang on Thursday October 26 at 1pm PST 4pm EST were delivery & platform expert Vince Kuraitis (@VinceKuraitis); author & ponderer of odd juxtapositions Kim Bellard (@kimbbellard); futurist Ian Morrison (@seccurve); and our special guest was Kat McDavitt(@katmcdavitt) President of Innsena.

The video is below. If you’d rather listen to the episode, the audio is preserved from Friday as a weekly podcast available on our iTunes & Spotify channels

THCB Gang Episode 136, Thursday October 5

Joining Matthew Holt (@boltyboy) on #THCBGang on Thursday October 5 at 1pm PST 4pm EST were delivery & platform expert Vince Kuraitis (@VinceKuraitis); author & ponderer of odd juxtapositions Kim Bellard (@kimbbellard) and policy expert consultant/author Rosemarie Day (@Rosemarie_Day1).

You can see the video below & if you’d rather listen than watch, the audio is preserved as a weekly podcast available on our iTunes & Spotify channels.

THCB Gang Episode 135, Thursday September 28

Joining Matthew Holt (@boltyboy) on #THCBGang on Thursday September 28 at 1pm PST 4pm EST are futurist Jeff Goldsmith: author & ponderer of odd juxtapositions Kim Bellard (@kimbbellard); and patient safety expert and all around wit Michael Millenson (@mlmillenson).

You can see the video below & if you’d rather listen than watch, the audio is preserved as a weekly podcast available on our iTunes & Spotify channels.

Shiv Rao, CEO demos Abridge

Abridge has been trying to document the clinical encounter automatically since 2018. There’s been quit a lot of fuss about them in recent weeks. They announced becoming the first “Pal” on the Epic “Partners& Pals” program, and also that their AI based encounter capture technology was now being used at several hospitals. And they showed up in a NY Times article about tech being used for clinical documentation. But of course they’re not the only company trying to turn the messy speech in a clinician/patient encounter into a buttoned-up clinical note. Suki, Augmedix & Robin all come to mind, while the elephant is Nuance, which has itself been swallowed by the whale that is Microsoft.

But having used their consumer version a few years back and been a little disappointed, I wanted to see what all the fuss was about. CEO Shiv Rao was a real sport and took me through a clinical example with him as the doc and me as a (slightly) fictionalized patient. He also patiently explained where the company was coming from and what their road map was. But they are all in on AI–no off shore typists trying to correct in close to real time here.

And you’ll for sure want to see the demo. (If you want to skip the chat it’s about 8.00 to 16.50). And I think you’ll be very impressed indeed. I know I was. I can’t imagine a doctor not wanting this, and I suspect those armies of scribes will soon be able to go back to real work! — Matthew Holt